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Abstract Cross-sectional studies show that frailty is
common in older people with cardiovascular disease.
Whether older people at higher risk of developing car-
diovascular disease are more likely to become frail is
unclear. We used multinomial logistic regression to
examine the prospective relation between Framingham
cardiovascular disease risk scores and incidence of
physical frailty or pre-frailty, defined according to the
Fried criteria, in 1,726 men and women aged 60 to over
90 years from the English Longitudinal Study of Ageing
who had no history of cardiovascular disease at baseline.
Men and women with higher Framingham cardiovascu-
lar risk scores were more likely to become frail over the
4-year follow-up period. For a standard deviation higher
score at baseline, the relative risk ratio (95 % confidence
interval) for incident frailty, adjusted for sex and base-
line frailty status, was 2.76 (2.18, 3.49). There was a
significant association between Framingham cardiovas-
cular risk score and risk of pre-frailty: 1.69 (1.46, 1.95).
After further adjustment for other potential confounding
factors, the relative risk ratios for frailty and pre-frailty
were 2.15 (1.68, 2.75) and 1.50 (1.29, 1.74), respective-
ly. The associations were unchanged after excluding
incident cases of cardiovascular disease. Separate ad-
justment for each component of the risk score suggested
that no single component was driving the associations
between cardiovascular risk score and incident pre-
frailty or frailty. Framingham cardiovascular risk scores
may be useful for predicting the development of phys-
ical frailty in older people. We now need to understand
the biological mechanisms whereby cardiovascular risk
increases the risk of frailty.
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Introduction
Frailty is a clinical syndrome observed in older people
whose core feature is an increased vulnerability to
stressors due to impairments in multiple, inter-related
systems, decreased physiological reserves and a decline
in the ability to maintain homeostasis (Bergman et al.
2007; Clegg et al. 2013). It is common (Gale et al.
2014a) and has numerous adverse consequences, in-
cluding disability, falls, morbidity, hospitalization, insti-
tutionalization and death. Its causes are complex and
likely to involve both biological and psychosocial
mechanisms (Rockwood et al. 1994; Walston et al.
2006).
Cross-sectional surveys show that frailty and chronic
disease frequently co-exist (Wong et al. 2010). One such
disease whose relationship with frailty has been the
focus of many studies is cardiovascular disease (CVD)
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(Afilalo et al. 2014; von Haehling et al. 2013). A sys-
tematic review of studies based on over 54,000
community-dwelling older people found that the odds
ratios for prevalent frailty associated with CVD ranged
from 2.7 to 4.1 (Afilalo et al. 2009) and that over a mean
follow-up period of 6 years, the presence of CVD in-
creased the risk of incident frailty by 50 %. These find-
ings suggest that CVD risk may be predictive of future
frailty and raise the possibility that multivariable risk
factor algorithms for assessing CVD risk in primary care,
such as that developed as part of the Framingham Heart
Study (D’Agostino et al. 2008), might provide a method
for identifying individuals currently free of CVDwho are
at increased risk of becoming frail. Longitudinal studies
in the Whitehall II cohort have shown that in middle-
aged people without a history of stroke or heart disease,
higher Framingham CVD risk scores are associated with
poorer performance on objective tests of physical func-
tion (Elbaz et al. 2014) and with increased later risk of
frailty (Bouillon et al. 2013), as defined by the Fried
physical frailty phenotype (Fried et al. 2001). Whether
such scores can predict future risk of frailty defined by
the Fried phenotype in older people is unknown.
The English Longitudinal Study of Ageing (ELSA)
is a large population-based sample of older men and
women. We used these data to investigate the prospec-
tive relation between Framingham CVD risk scores and
risk of incident frailty in men and women aged 60 to
over 90 years (Marmot et al. 2013).
Methods
Participants
The data for this study come from the ELSA. The
sample for ELSA was based on people aged ≥50 years
who had participated in the Health Survey for England
in 1998, 1999 or 2001 (Steptoe et al. 2013). It was
drawn by postcode sector, stratified by health authority
and proportion of households in non-manual socioeco-
nomic groups. A total of 11,392 people participated in
wave 1 in 2002–2003. At wave 2 in 2004–2005 and at
wave 4 in 2008–2009, core sample members (those in
the household aged ≥50 years who had taken part in
wave 1) who had completed the main interview were
invited to have a visit from a nurse that included mea-
surements of physical function and blood pressure, an-
thropometry and blood sampling. Ethical approval was
obtained from the Multicentre Research and Ethics
Committee. Participants gave written informed consent.
Measures
Frailty
Maximum handgrip strength was measured three times
on each side using a dynamometer; the best of these
measurements was used for analysis. Height and weight
were measured with a portable stadiometer and elec-
tronic scales, respectively. Body mass index (BMI) was
calculated as weight (in kilograms)/height (in metres)2.
Gait speed was assessed in participants aged 60 and over
by measuring the time taken to walk a distance of 8 ft at
usual pace; the timed walk was repeated, and the mean
of the two measurements was calculated. Participants
responded to three questions about the frequency with
which they did vigorous, moderate or mild exercise. We
ranked the combinations of responses to these questions
according to the amount and intensity of exercise in-
volved to provide an estimate of usual physical activity.
Symptoms of depression were assessed using the eight-
item version of the Centre for Epidemiologic Studies
Depression Scale (CES-D) (Steffick and The HRS
working group 2000). We used these data, together with
information on participants’ weight at the initial survey,
to derive an indicator of physical frailty at wave 2
(baseline) and at wave 4 in men and women aged
≥60 years using the Fried criteria (Fried et al. 2001).
These criteria define physical frailty as the presence of
three or more of the following: unintentional weight
loss, weakness, self-reported exhaustion, slow walking
speed and low physical activity. We operationalized
these criteria using definitions very similar to those used
in the original phenotype of frailty studies (Bandeen-
Roche et al. 2006; Fried et al. 2001): Weight loss was
defined as either loss of ≥10 % of body weight since the
initial survey (for frailty at wave 2) or since wave 2 (for
frailty at wave 4) or current BMI <18.5 kg/m2; weak-
ness was defined as maximum grip strength in the
lowest 20 % of the distribution, after taking sex and
BMI into account; exhaustion was considered present if
the participant gave a positive response to either of the
CES-D questions ‘Felt that everything I did was an
effort in the last week’ or ‘Could not get going in the
last week’; slow walking speed was defined as a walk-
ing speed in the lowest 20 % of the distribution, after
taking account of sex and height; participants who did
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not perform the timed walk because they were unable to
walk alone or had health restrictions were also
categorised as having slow walking speed;and low
physical activity was defined as physical activity in the
lowest sex-specific 20 % of the distribution.
Framingham cardiovascular risk score at baseline
The Framingham general cardiovascular risk score was
developed for use in primary care to assess general
cardiovascular risk and risk of individual events (coro-
nary, cerebrovascular, peripheral arterial disease and
heart failure) (D’Agostino et al. 2008). Its sex-specific
algorithm is based on age, HDL and total cholesterol,
systolic blood pressure, treatment for hypertension,
smoking and diabetes.
Data on the risk score components was taken from
the wave 2 examination. Blood samples were taken
from all participants except those who were not willing
to give written consent, those with clotting or bleeding
disorders and those taking anti-coagulant drugs. Sam-
ples were assayed for total and HDL cholesterol,
haemoglobin A1C and in addition for fibrinogen and
C-reactive protein at the Royal Victoria Infirmary,
Newcastle-upon-Tyne, UK. Systolic blood pressure
was measured three times using an Omron blood pres-
sure monitor with the participant seated. We used the
mean of these three values in our analysis. Participants
were asked whether they were currently taking any med-
ication for high blood pressure and about their current
smoking status. Prevalent diabetes mellitus was defined
based on reported doctor-diagnosed diabetes and/or use
of diabetes medication, or a haemoglobin A1C level
≥6.5 % (The International Expert Committee 2009).
Covariates at baseline
We chose cognitive function, household wealth and BMI
as covariates because they could potentially confound
any association between Framingham CVD risk score
and later risk of frailty. Poorer cognition, lower socioeco-
nomic status, as measured by household wealth, and
higher BMI are independent predictors of frailty in both
men and women in this cohort (Gale et al. 2014b), and
have been shown to correlate with higher Framingham
CVD risk scores (Elbaz et al. 2014; Kaffashian et al.
2013). Participants took tests of cognitive function as
follows: Verbal memory (immediate and delayed recall
of ten aurally presented nouns) was assessed using word
lists developed for the US Health and Retirement Study
(Ofstedal et al. 2005); prospective memory (remember-
ing to do a specific task) and attention (letter cancellation
task) were assessed using tests previously used in the
MRC Cognitive Function and Ageing Study (Brayne
et al. 1998); and executive function was assessed using
a test of verbal (semantic) fluency (naming as many
animals as possible in 60 s) taken from the CAMCOG-
R (Roth et al. 1999). A total cognitive function score was
calculated by summing scores on these tests. Socioeco-
nomic status was indexed by total household wealth,
including savings and investments, value of any property
or business assets, net of debt, excluding pension assets.
Household wealth has been identified as the most accu-
rate indicator of long-term socioeconomic circumstances
in ELSA (Banks et al. 2003).
In a previous study of this cohort, higher concentra-
tions of the inflammatory markers fibrinogen and C-
reactive protein were significant predictors of incident
frailty in women, though not in men (Gale et al. 2013).
As higher levels of these biomarkers correlate with
higher Framingham CVD risk scores (Noh et al. 2013;
Park et al. 2010), they might potentially confound any
link between these risk scores and frailty, at least in
women. We therefore carried out a subset analysis in
which we examined whether additional adjustment for
concentrations of fibrinogen and C-reactive protein al-
tered the association between Framingham CVD scores
and risk of frailty.
Analytical sample
Of the 5,918 study members aged ≥60 years who were
interviewed at wave 2 in 2004–2005, 5,377 agreed to be
visited by a nurse (91 %). Of these, 3,454 were
interviewed and visited by a nurse at wave 4 in 2008–
2009. We excluded prevalent cases of CVD at the wave
2 baseline (reported doctor diagnoses of angina, heart
attack, congestive heart failure or stroke). The present
analysis is based on 1,726 people who were free of CVD
at baseline and had complete data on Framingham car-
diovascular risk score and baseline covariates at wave 2
and frailty at wave 4.
Statistical analysis
We used ANOVA and chi-square test to examine differ-
ences in baseline characteristics according to the pres-
ence of pre-frailty or frailty at follow-up. We used
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multinomial logistic regression to examine the relation
between a standard deviation increase in Framingham
CVD risk score at baseline and risk of incident pre-
frailty or frailty. We adjusted for sex and frailty status
at baseline and then in addition for cognitive function,
household wealth and BMI. In a subset of women only,
we carried out an additional adjustment for the inflam-
matory biomarkers fibrinogen and C-reactive protein. In
order to examine which components of the Framingham
CVD risk score helped to explain its association with
incident frailty, we examined the effect on the associa-
tion of adjusting for each component (age, HDL and
total cholesterol, systolic blood pressure, treatment for
hypertension, smoking and diabetes) in turn.
All data were weighted to correct for sampling prob-
abilities, non-response, and for differential sample loss
between waves in order to make them more closely
reflect the population from whom the ELSA sample
was drawn. Detailed descriptions of these weights and
their calculation can be found in the technical reports on
the study available at www.ifs.org.uk/elsa.
Results
Table 1 shows the baseline characteristics of the 1,726
men and women in the study according to whether they
were not frail, pre-frail or frail at follow-up. The weight-
ed percentage of participants who were pre-frail or frail
at follow-up was 43 and 13 %, respectively. Mean
Framingham CVD risk score at baseline rose with in-
creasing degree of frailty at follow-up and differed sig-
nificantly between those who were not frail, pre-frail or
frail. As regards to the components of the Framingham
CVD risk score, men and women who were older or
who had diabetes at baseline tended to have a higher
degree of frailty at follow-up. People who were pre-frail
had higher systolic blood pressure at baseline than those
who were not frail, but there were no differences in
blood pressure between those who were pre-frail and
those who were frail. Compared to those who were not
frail at follow-up, those who were pre-frail were slightly
more likely to have been a smoker at baseline, but this
was of borderline significance, and there were no dif-
ferences in baseline smoking status between those who
were pre-frail and those who were frail at follow-up.
Blood levels of total or HDL cholesterol and use of anti-
hypertensive medication at baseline did not vary signif-
icantly by frailty status at follow-up. As regards to the
covariates, cognitive function was poorer, level of
household wealth lower and BMI higher at baseline in
those with a greater degree of frailty at follow-up. There
was no difference in sex distribution between those who
were not frail and those who were pre-frail at follow-up,
Table 1 Baseline characteristics of the study participants (n=1,726) according to frailty status at follow-up
Not frail
(n=862)
Pre-frail
(n=691)
Frail
(n=173)
P for difference
between not frail
and pre-frail
P for difference
between pre-frail
and frail
Framingham CVD risk score, mean (SD) 14.3 (2.59) 15.3 (2.48) 16.1 (2.35) <0.0001 <0.0001
Framingham CVD risk score components
Age (years), mean (SD) 67.1 (6.20) 71.6 (7.33) 76.2 (7.83) <0.0001 0.005
HDL cholesterol (mg/dl), mean (SD) 61.0 (16.1) 60.1 (15.0) 60.7 (14.3) 0.261 0.267
Total cholesterol (mg/dl), mean (SD) 236.8 (50.2) 236.6 (46.2) 235.9 (47.1) 0.838 0.705
Current smoker, % 7.40 9.95 12.9 0.086 0.334
Systolic blood pressure (mm Hg), mean (SD) 135.9 (19.9) 139.5 (19.0) 141.2 (19.0) 0.001 0.465
On anti-hypertensive medication, % 13.7 16.0 15.5 0.238 0.882
Diabetes, % 5.99 7.16 16.6 0.001 0.004
Covariates
Female, % 55.1 56.6 67.7 0.573 0.012
Cognitive function, mean (SD) 30.2 (5.74) 27.5 (5.52) 24.7 (4.96) <0.0001 <0.0001
Lowest quintile of household wealth, % 9.09 18.5 29.4 <0.0001 <0.0001
BMI (kg/m2), mean (SD) 27.2 (4.24) 27.5 (4.39) 28.7 (5.24) 0.031 0.006
No of frailty criteria present, mean (SD) 0.29 (0.65) 0.79 (0.85) 1.65 (1.14) <0.0001 <0.0001
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but there was a significantly higher proportion of wom-
en among those who were frail.
Preliminary analyses showed that the relationship
between Framingham CVD risk score and risk of inci-
dent pre-frailty or frailty did not differ between the sexes
(p for interaction term >0.5). Multivariate multinomial
logistic regression analyses of frailty risk were therefore
carried out in men and women together, adjusting for
sex.
Table 2 shows relative risks for incident pre-frailty
and frailty for a standard deviation increase in Framing-
ham CVD risk score. Results are shown adjusted first
for sex and baseline frailty status, and then with further
adjustment for the other potential confounding vari-
ables, household wealth, cognitive function and BMI.
In models adjusting for sex and baseline frailty status,
there was a significant positive association between
Framingham CVD risk score at baseline and risk of
incident frailty: For a standard deviation increase in
the Framingham risk score, the relative risk ratio (RR)
(95 % confidence interval) for incident frailty was 2.76
(2.18, 3.49). Further adjustment for cognitive function,
household wealth and BMI at baseline only partially
attenuated the association: RR (95 % CI) 2.15 (1.68,
2.75). There was a significant association between total
score for Framingham CVD risk score at baseline and
risk of incident pre-frailty: For a standard deviation
increase in the Framingham risk score, the relative risk
ratio (95 % confidence interval) for incident pre-frailty
was 1.69 (1.46, 1.95). Further adjustment for cognitive
function, household wealth and BMI at baseline had
only minor attenuating effects: RR (95 % CI) 1.50
(1.29, 1.74).
None of the participants in our sample had a reported
history of CVD at baseline. To examine whether the
associations between baseline Framingham CVD risk
score and incident frailty or pre-frailty were concentrat-
ed among those who reported that they had been newly
diagnosed with CVD during the 4-year follow-up
period, we repeated our analysis after excluding this
group (n=68). Results were essentially unchanged.
In a subset analysis of the women in our sample
(n=982), we examined whether concentrations of the
inflammatory markers fibrinogen and C-reactive pro-
tein—previously shown to be predictive of frailty in
women only (Gale et al. 2013)—were confounders of
the associations between baseline Framingham CVD
risk score and incident frailty or pre-frailty. Adjustment
for these biomarkers had little attenuating effect. For an
SD increase in FraminghamCVD score, the relative risk
ratios for incident pre-frailty or frailty in women, adjust-
ed for baseline frailty status, were 1.63 (1.34, 1.98) and
2.51 (1.87, 3.38), respectively. After further adjustment
for baseline fibrinogen and C-reactive protein levels,
these relative risk ratios were 1.61 (1.32, 1.96) and
2.34 (1.73, 3.18), respectively.
In order to investigate whether the associations ob-
served between the Framingham CVD score at baseline
and risk of incident frailty or pre-frailty were driven by
particular components of the score (age, systolic blood
pressure, use of anti-hypertensive medication, current
smoking, HDL and total cholesterol and diabetes), we
examined the effect on the sex and baseline frailty status-
adjusted relative risks of further adjustment for each
component in turn. The associations between CVD risk
score and risk of pre-frailty and frailty were in almost all
cases unattenuated by these adjustments (Table 3). The
largest attenuating effects occurred when the associations
between Framingham CVD risk score and risk of pre-
frailty or frailty were adjusted for age, but they remained
statistically significant: Relative risk ratios for pre-frailty
or frailty changed from 1.69 (1.46, 1.95) and 2.76 (2.18,
3.49) to 1.24 (1.05, 1.46) and 1.71 (1.31, 2.24), respec-
tively. Adjustment for diabetes, the only component of
the Framingham risk score apart from age that was
consistently and strongly linked with frailty status (see
Table 1), had no attenuating effect on the associations
between CVD risk score and risk of pre-frailty and frailty.
Table 2 Relative risk ratios (95 % CI) for incident pre-frailty or frailty for a standard deviation increase in Framingham CVD risk score at
baseline
RR (95 % CI), adjusted for sex and
baseline frailty status
RR (95 % CI), fully adjusted1
Pre-frailty Frailty Pre-frailty Frailty
Framingham CVD risk score, per SD increase 1.69 (1.46, 1.95.) 2.76 (2.18, 3.49) 1.50 (1.29, 1.74) 2.15 (1.68, 2.75)
1 Adjusted for sex, household wealth, cognitive function, BMI, and whether non-frail, pre-frail or frail at baseline
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To explore whether the associations might be better
explained by a continuous measure of glucose metabo-
lism, we adjusted for levels of haemoglobin A1C, but this
too had no attenuating effect (data not shown). These
results suggest that no specific component risk factor
drives the associations between Framingham CVD risk
score and risk of pre-frailty or frailty.
Discussion
In this prospective study of men and women aged 60 to
over 90 years, none of whom had a history of CVD,
higher Framingham CVD risk scores at baseline were
associated with an increased risk of incident frailty and
pre-frailty. Adjustment for potential confounding factors
had only small attenuating effects on these associations,
and they were little changed by the exclusion of those
who developed CVD during follow-up.
To our knowledge, only one previous study has ex-
amined the relation between Framingham CVD risk
scores and subsequent frailty. In the Whitehall II study,
an SD increase in Framingham CVD score in people
aged 45–69 years increased the odds of being frail
10 years later by 42 % (Bouillon et al. 2013). As in the
present study, no single component of the CVD risk score
appeared to be driving its association with future frailty.
Direct comparison of effect sizes with those found in our
study is difficult because we usedmultinomial rather than
binary logistic regression so that we could examine
whether Framingham CVD score was linked with risk
of pre-frailty as well as frailty, but our findings suggest
that the risk of frailty associated with raised Framingham
CVD scores in older people is at least as high and
possibly higher than that observed in middle-aged indi-
viduals. Furthermore, our results suggest that these CVD
scores are also predictive of risk of pre-frailty—defined
by Fried as the presence of just one or two of the five
components of frailty (Fried et al. 2001). This has poten-
tial implications for prevention or amelioration. Whereas
transitions to a state of greater frailty are more common
than movement in the reverse direction, there is sufficient
evidence of the latter to suggest that frailty is potentially
reversible, at least in the less severe stage (Espinoza et al.
2012; Gill et al. 2006).
Several mechanisms could potentially underlie the
association we observed between Framingham CVD
risk scores in people with no known history of CVD
and later risk of frailty. One possibility is that athero-
sclerosis affects blood flow to the nerves and muscles of
the legs, exacerbating sarcopenia, a major component of
frailty (Morley et al. 2002). There is some evidence that
the prevalence of frailty is higher in older people with
peripheral atherosclerosis as indicated by a high ankle-
brachial index or other indicators of subclinical CVD
such as carotid stenosis or left ventricular hypertrophy
(Newman et al. 2001; Singh et al. 2012). In the Three
Cities study of older people, mean walking speed de-
creased with increasing number of carotid plaques and
increased intimal-medial thickening (Elbaz et al. 2005).
Another related factor might be brain pathology. Brain
autopsy in members of two US cohorts—the Religious
Orders Study and the Rush Memory and Aging Pro-
ject—followed for up to 14 years showed that the pres-
ence of subclinical CVD and Alzheimer pathologies
was associated with more rapid progression of frailty,
and in particular with more rapid decline in walking
speed (Buchman et al. 2013). Although inflammation
Table 3 Relative risk ratios
(95 % CI) for incident pre-frailty
or frailty for a standard deviation
increase in Framingham CVD
risk score at baseline, separately
adjusted for each component of
the score
Framingham CVD risk score, per SD increase RR (95 % CI
Pre-frailty Frailty
Adjusted for sex and baseline frailty status 1.69 (1.46, 1.95) 2.76 (2.18, 3.49)
Further adjusted for:
Age 1.24 (1.05, 1.46) 1.71 (1.31, 2.24)
Total cholesterol 1.74 (1.50, 2.02) 2.89 (2.28, 3.67)
HDL cholesterol 1.68 (1.45, 1.84) 2.87 (2.25, 3.67)
Systolic blood pressure 1.63 (1.46, 1.95) 2.62 (2.07, 3.33)
Anti-hypertensive treatment 1.65 (1.45, 1.87) 2.76 (2.18, 3.49)
Smoking 1.69 (1.46, 1.95) 3.13 (2.43, 4.04)
Diabetes 1.80 (1.53, 2.11) 2.77 (2.12, 3.61)
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is a plausible underlying mechanism, given observa-
tions in several studies linking higher levels of inflam-
matory biomarkers with higher CVD risk scores (Noh
et al. 2013; Park et al. 2010) and increased risk of
incident frailty (Baylis et al. 2012; Puts et al. 2005),
we found little evidence that it played a part in the
associations we found. Another potential underlying
mechanism is impaired glucose metabolism. There is
evidence that muscle strength and physical function are
poorer in older people with raised glucose levels, and
this is not confined to those with diabetes (Sayer et al.
2005). Diabetes has been linked with increased risk of
becoming frail (Lee et al. 2014), perhaps by accelerating
age-related muscle loss (Kalyani et al. 2014). However,
in this study, although the presence of diabetes at base-
line was strongly associated with greater frailty at
follow-up, neither it nor levels of a baseline marker of
glucose metabolism—haemoglobin A1C—helped to
explain the association between Framingham CVD risk
scores and incident pre-frailty or frailty.
The strengths of our study include the large sample
size, the fact that ELSAwas designed to be representa-
tive of the older community-dwelling English popula-
tion (Steptoe et al. 2013), and our use of a prospective
study design in which we assessed incident cases of pre-
frailty or frailty that occurred after the measurement of
CVD risk factors. There are also some weaknesses.
First, information on prevalent and incident CVD was
based solely on reported doctor diagnoses of angina,
heart attack, congestive heart failure or stroke. Second,
not all the participants in the baseline survey gave a
blood sample (77 % of those interviewed); non-
responders to the blood sample tended to be older and
in poorer health. However, in view of the fact that the
associations we found between Framingham CVD risk
score and risk of frailty were at least as strong as those
reported in a previous study of middle-aged people
(Bouillon et al. 2013), it seems unlikely that our findings
would be very different if we had validated data on
history of CVD and complete data on blood biomarkers
for all those who were interviewed at baseline. Finally,
our follow-up period was relatively short—around
4 years—which raises the possibility of reverse causa-
tion whereby the higher baseline Framingham CVD risk
scores observed in people who were frail or pre-frail at
follow-up might be a consequence of their prior frailty
status. We can be fairly sure that this is not the case as
the association we found was robust to adjustment for
the number of components of frailty present at baseline.
Furthermore, it is consistent with observations from
other longitudinal studies with much longer follow-up
times that higher levels of cardiovascular risk factors in
midlife—whether assessed as overweight or obesity
(Stenholm et al. 2014), physical activity (Savela et al.
2013) or a composite risk factor score for coronary
artery disease (Strandberg et al. 2012)—increase the risk
of frailty over 20 years later.
In this prospective study of men and women aged 60
to over 90 years, none of whom had a history of CVD;
higher Framingham CVD risk scores were associated
with an increased risk of incident frailty and pre-frailty.
Use of these scores in clinical practice may help identify
those older people who are at risk of becoming frail. We
now need to understand the biological mechanisms
whereby CVD risk increases the risk of frailty.
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